Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
JOURNAL OF CLINICAL ONCOLOGY. Bd. 38. H. 4. 2020
Erscheinungsjahr: 2020
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Galle, Peter R. (Autor)
Finn, Richard S. (Autor)
Qin, Shukui (Autor)
Ikeda, Masafumi (Autor)
Zhu, Andrew X. (Autor)
Kim, Tae-You (Autor)
Kudo, Masatoshi (Autor)
Breder, Valeriy Vladimirovich (Autor)
Merle, Philippe (Autor)
Kaseb, Ahmed Omar (Autor)
Li, Daneng (Autor)
Mulla, Sohail (Autor)
Verret, Wendy (Autor)
Xu, Derek-Zhen (Autor)
Hernandez, Sairy (Autor)
Liu, Juan (Autor)
Huang, Chen (Autor)
Lim, Ho Yeong (Autor)
Cheng, Ann-Lii (Autor)
Ducreux, Michel (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
